PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - PTC Therapeutics reported a quarterly loss of $1.39 per share, which was better than the Zacks Consensus Estimate of a loss of$1.54, marking an earnings surprise of 9.74% [1] - The company generated revenues of $196.79 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 13.41$196.58 million year-over-year [2] - PTC Therapeutics shares have appreciated approximately 56.7% year-to-date, outperforming the S&P 500's gain of 24.3% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.64 on revenues of$167.26 million, while for the current fiscal year, it is -$5.28 on revenues of$731.88 million [7] - The estimate revisions trend for PTC Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which PTC Therapeutics belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Theravance Biopharma, is expected to report a quarterly loss of $0.10 per share, reflecting a significant year-over-year decline of 900% [9]